Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.

1997 ◽  
Vol 15 (6) ◽  
pp. 2385-2393 ◽  
Author(s):  
J D Hainsworth ◽  
J B Erland ◽  
L A Kalman ◽  
M T Schreeder ◽  
F A Greco
Keyword(s):  
Primary Tumor ◽  
Site Response ◽  
Response Rates ◽  
Unknown Primary ◽  
Tumor Site ◽  
Unknown Primary Tumor ◽  
Primary Tumor Site ◽  
Carcinoma Of Unknown Primary ◽  
Poorly Differentiated Neuroendocrine Carcinoma ◽  
Poorly Differentiated

PURPOSE To evaluate the efficacy and toxicity of a novel chemotherapy combination that includes paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of patients with carcinoma of unknown primary tumor site. PATIENTS AND METHODS Fifty-five patients with carcinoma of unknown primary tumor site were treated with the following regimen, administered every 21 days: paclitaxel 200 mg/m2 by 1-hour intravenous (I.V.) infusion on day 1, carboplatin at an estimated area under the concentration-time curve (AUC) of 6.0 on day 1, and etoposide 50 mg alternated with 100 mg orally on days 1 through 10. Responding patients received a total of four courses of treatment. The following histologies were included: adenocarcinoma, 30 patients; poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA), 21; poorly differentiated neuroendocrine carcinoma, three; and squamous carcinoma, one. RESULTS Twenty-five of 53 assessable patients (47%; 95% confidence interval [CI], 33% to 61%) had major objective responses to treatment (seven complete responses). Response rates were similar in patients with adenocarcinoma versus PDC (45% and 48%, respectively). The actuarial median survival time for the entire group was 13.4 months. The regimen was well tolerated, with only seven hospitalizations for treatment of neutropenia and fever (4% of courses) and no treatment-related deaths. CONCLUSION The combination of paclitaxel, carboplatin, and extended-schedule etoposide is highly active and well tolerated in patients with carcinoma of unknown primary tumor site. Response rates and survival in this multicenter community-based trial compare favorably with all previously studied empiric regimens. In addition, this regimen is substantially less toxic and easier to administer than the cisplatin-based regimens previously used in this setting. If this level of efficacy is confirmed, this treatment should be considered standard first-line therapy in patients with carcinoma of unknown primary tumor site.

Risk factors for survival from neuroendocrine neoplasia with unknown primary tumor site

2014 ◽  
Vol 219 (4) ◽  
pp. e84
Author(s):  
Nehara Begum ◽  
Ulrich F. Wellner ◽  
Christoph Thorns ◽  
Martin Hoffmann ◽  
Conny G. Bürk ◽  
...  
Keyword(s):  
Risk Factors ◽  
Primary Tumor ◽  
Unknown Primary ◽  
Tumor Site ◽  
Unknown Primary Tumor ◽  
Primary Tumor Site ◽  
Neuroendocrine Neoplasia ◽  
Risk Factors For Survival

scholarly journals Human Papillomavirus and Squamous Cell Carcinoma of Unknown Primary in the Head and Neck Region: A Comprehensive Review on Clinical Implications

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1297
Author(s):  
Mikkel Hjordt Holm Larsen ◽  
Hani Ibrahim Channir ◽  
Christian von Buchwald
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Unknown Primary ◽  
Diagnostic Strategy ◽  
Primary Tumor Site ◽  
Carcinoma Of Unknown Primary ◽  
Diagnostic Modalities

Squamous cell carcinoma of unknown primary (SCCUP) is a challenging diagnostic subgroup of oropharyngeal squamous cell carcinoma (OPSCC). The incidence of SCCUP is increasing in parallel with the well-documented increase in OPSCC and is likewise driven by the increase in human papillomavirus (HPV). The SCCUP patient often presents with a cystic lymph node metastasis and undergoes an aggressive diagnostic and treatment program. Detection of HPV in cytologic specimens indicates an oropharyngeal primary tumor origin and can guide the further diagnostic strategy. Advances in diagnostic modalities, e.g., transoral robotic surgery and transoral laser microsurgery, have increased the successful identification of the primary tumor site in HPV-induced SCCUP, and this harbors a potential for de-escalation treatment and increased survival. This review provides an overview of HPV-induced SCCUP, diagnostic modalities, and treatment options.

scholarly journals UNKNOWN PRIMARY TUMOR SITES IN SPINAL METASTASIS

2021 ◽  
Vol 20 (1) ◽  
pp. 64-67
Author(s):  
Priscila Barile Marchi Candido ◽  
Rômulo Pedroza Pinheiro ◽  
Fernanda Maris Peria ◽  
Vinicius Nogueira Toledo ◽  
Herton Rodrigo Tavares Costa ◽  
...  
Keyword(s):  
Clinical Features ◽  
Primary Tumor ◽  
Spinal Metastasis ◽  
Survival Rates ◽  
Unknown Primary ◽  
Unknown Primary Tumor ◽  
Treatment Results ◽  
Level Of Evidence ◽  
Primary Tumor Site ◽  
Epidural Compression

ABSTRACT Objective: The goal of the study was to report the prevalence of spinal metastasis with unknown primary tumor, clinical features, treatment results and patient survival. Methods: A retrospective evaluation of 103 patients with spinal metastasis and epidural compression, who underwent surgical treatment between March 2009 and August 2015. The prevalence of metastatic spinal tumor with unknown primary tumor was evaluated, as well clinical features, survival and treatment results. Results: Of 103 patients with spinal metastasis and epidural compression, seven patients (6.8%) with unknown primary tumor site were identified; five (71.4%) male and two (28.6%) female, with ages ranging from 37 to 67 years (50.7 years). The metastasis was located in the thoracic spine in six of the patients (85.7%) and in the cervical spine in one (14.3%). The mean survival time was 44.8 days. Conclusion: Spinal metastasis with unknown primary tumor was found in 6.8% of patients. The prognosis and outcomes were poor, and patients had poor survival rates. Level of evidence III; Experimental study.

Correlation of SPARC expression and primary tumor site response(PTSR) and relapse to nab-paclitaxel vs docetaxel-based induction chemotherapy (IC) in patients(Pts) with HNSCC.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e17079-e17079
Author(s):  
Jon Chatzkel ◽  
James S. Lewis ◽  
Jessica C. Ley ◽  
Loren S. Michel ◽  
Tanya Marya Wildes ◽  
...  
Keyword(s):  
Induction Chemotherapy ◽  
Primary Tumor ◽  
Site Response ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Sparc Expression

Can Computed Tomography Characteristics of the Oropharynx in Cancer of Unknown Primary Predict Primary Tumor Site?

2014 ◽  
Vol 151 (1_suppl) ◽  
pp. P157-P158
Author(s):  
Ryan P. McSpadden ◽  
Thomas P. Sullivan ◽  
Jordan Rosenblum ◽  
Carol M. Bier-laning
Keyword(s):  
Computed Tomography ◽  
Primary Tumor ◽  
Cancer Of Unknown Primary ◽  
Unknown Primary ◽  
Tumor Site ◽  
Primary Tumor Site

The role of whole body 18F-FDG PET/CT scan in patients with carcinoma of unknown primary

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e22051-e22051
Author(s):  
M. Hu ◽  
J. Yu ◽  
N. Liu ◽  
L. Kong ◽  
P. Zhang
Keyword(s):  
Ct Scan ◽  
Primary Tumor ◽  
Fdg Pet ◽  
Primary Site ◽  
Unknown Primary ◽  
Tumor Site ◽  
Primary Tumor Site ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

e22051 Background: Carcinoma of unknown primary (CUP) is a heterogeneous group of tumors and usually follows an aggressive biological and clinical behavior. Difficult challenges in oncology which the identification of the primary tumor and a complete disease staging could offer a more rational and efficient treatment in order to improve the survival time. Our aim was to evaluate the role of 18F-FDG PET/CT scan with two aspects: detection of the primary site, and estimation of tumor biological behavior which essential for the development of new, individual and targeted effective therapies. Methods: One hundred and seventeen patients presenting with histologically confirmed metastatic carcinoma (76 lymph nodes, 41 visceral biopsy proven) of unknown primary site were included in this retrospective study. The evaluations as follows had not revealed a primary site: detailed medical history, full physical and laboratory examinations, and diagnostic imaging methods. All patients underwent PET/CT. Results: In 42 (35.90%) patients, a primary tumor site which was confirmed by follow-up or surgery was showed by PET/CT. In 15 (12.82%) patients, the primary tumor site was suggested by PET/CT but not confirmed. In 60 (51.28%) patients, the primary tumor site was not localized modifying the stage of disease. In the other 17 (14.53%) patients, PET/CT scan identified further unexpected metastases. Overall, the following oncological treatment was influenced by the PET/CT scan, in a total of 38 (32.47%) patients. Between the adenocarcinoma and squamous cell carcinoma groups, no significant difference in SUVmax was found ( t=1.191, p = 0.244). A significantly higher SUVmax was found among patients with poorly or undifferentiated carcinoma compared with patients with well to moderately ( t=4.013, p<0.01) differentiation; In 42 patients with a confirmed primary tumor site, the SUVmax of Metastatic tumours have a closely relationship correlate with those of primary tumours, ( r=0.738, p<0.01). Furthermore, a significantly higher SUVmax was found among metastases compared with primary tumors ( t=3.470, p<0.01). Conclusions: Our data strongly support 18F-FDG PET/ CT imagings not only provide new insights in the diagnosis and staging of patients with CUP, but also evaluate biologic characters of tissue. 1 No significant financial relationships to disclose.

Squamous cell carcinoma of unknown primary tumor metastatic to neck nodes: role of elective irradiation

2016 ◽  
Vol 273 (12) ◽  
pp. 4561-4569 ◽  
Author(s):  
Primož Strojan ◽  
Marko Kokalj ◽  
Vesna Zadnik ◽  
Aleksandar Aničin ◽  
Gaber Plavc ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Unknown Primary ◽  
Unknown Primary Tumor ◽  
Carcinoma Of Unknown Primary
Sign in / Sign up

Export Citation Format

Share Document